Skip to main content

Advertisement

SpringerLink
Log in

Clinical features of Behçet’s disease and prediction of the use of biologics in 488 cases: a single tertiary center study

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objectives are to describe the demographic and clinical properties of Behçet's disease (BD) and investigate their relationship with the use of biological agents. Four hundred-eighty-eight patients, (299 (61.3%) males, 189 (38.7%) females), who fulfilled the ISG classification criteria for BD were included, retrospectively. The patient's demographics, disease onset age (DOA), clinical findings of the disease, and the drugs were determined and analyzed statistically. The means of patient age and DOA were 40.7 ± 9.9 and 30.8 ± 8.8 years, respectively. The most common initial findings were oral ulcer (OU)s (30.1%), genital ulcer (GU) (27.5%), ocular involvement (OI) (12.5%), and papulopustular lesion (PPL)s (10.1%). The most common clinical manifestations were OUs (96.9%), PPLs (70.2%), HLA-B51 (64.4%), positive pathergy reaction (26.4%), GU (58.8%), OI (44.7%), erythema nodosum (29.8%), and vascular involvement (VSI) (27.3%). Although, the frequency of GU was higher in females (p = 0.01), PPLs (p = 0.001) and VSI (p = 0.001) were higher in males. Sixty-three (8.9%) patients used a biological agent. Its frequency was higher in younger patients (< 40 years) (p = 0.006), males (p = 0.012) and patients with OI (p = 0.001). Besides, the DOA (p = 0.012) and the current age (p = 0.001) were lower in biological agent users. The possibility of using biological agent was increased in males (OR = 2.2), patients with OI (OR = 2.7) and young patients (OR = 0.9). Mucocutaneous lesions are distinctive features of BD, especially OUs precede other findings. GU was more common in females and PPLs and VSI were in males. The probability of using biologics is higher in males, patients with OI, and young patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The obtained data of this study are present in the repository of the corresponding author. It can be made available to researchers for academic research upon request.

References

  1. Tan SY, Poole PS (2016) Hulusi behçet (1889–1948): passion for dermatology. Singapore Med J. 57(7):408–9. https://doi.org/10.11622/smedj.2016123

    Article  PubMed  PubMed Central  Google Scholar 

  2. Yazici Y, Hatemi G, Bodaghi B et al (2021) Behçet syndrome. Nat Rev Dis Primers 7(1):67. https://doi.org/10.1038/s41572-021-00301-1

    Article  PubMed  Google Scholar 

  3. Adil A, Goyal A, Quint JM (2023) Behcet disease. StatPearls Publishing, Treasure Island

    Google Scholar 

  4. Davatchi F, Chams-Davatchi C, Shams H et al (2017) Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 13(1):57–65. https://doi.org/10.1080/1744666X.2016.1205486

    Article  CAS  PubMed  Google Scholar 

  5. Cansu DÜ, Kaşifoğlu T, Korkmaz C (2016) Do clinical findings of Behçet’s disease vary by gender?: A single-center experience from 329 patients. Eur J Rheumatol 3(4):157–160. https://doi.org/10.5152/eurjrheum.2016.038

    Article  PubMed  PubMed Central  Google Scholar 

  6. Karincaoglu Y, Borlu M, Toker SC et al (2008) Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 58(4):579–584. https://doi.org/10.1016/j.jaad.2007.10.452

    Article  PubMed  Google Scholar 

  7. Tong B, Liu X, Xiao J, Su G (2019) Immunopathogenesis of Behcet’s disease. Front Immunol 10:665. https://doi.org/10.3389/fimmu.2019.00665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lopalco G, Rigante D, Lopalco A, Emmi G, Venerito V, Vitale A, Capozio G, Denora N, Cantarini L, Iannone F (2020) Safety of systemic treatments for Behçet’s syndrome. Expert Opin Drug Saf 19(10):1269–1301. https://doi.org/10.1080/14740338.2020.1817379

    Article  CAS  PubMed  Google Scholar 

  9. Vural S, Boyvat A (2022) The skin in Behçet’s disease: mucocutaneous findings and differential diagnosis. JEADV Clin Pract 1:11–20

    Article  Google Scholar 

  10. Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119. https://doi.org/10.1038/nrrheum.2017.208

    Article  CAS  PubMed  Google Scholar 

  11. Alibaz-Oner F, Direskeneli H (2022) Update on the diagnosis of Behçet’s disease. Diagnostics (Basel) 13(1):41. https://doi.org/10.3390/diagnostics13010041

    Article  PubMed  Google Scholar 

  12. Nakamura K, Tsunemi Y, Kaneko F, Alpsoy E (2021) Mucocutaneous manifestations of Behçet’s disease. Front Med (Lausanne). 7:613432. https://doi.org/10.3389/fmed.2020.613432

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gürbüz C, Yalçın Kehribar D, Özgen M (2021) Clinical manifestations of Behçet’s syndrome: a single-center cohort of 777 patients. Eur J Rheumatol 8(4):211–216. https://doi.org/10.5152/eurjrheum.2020.21199

    Article  PubMed  Google Scholar 

  14. Uygunoğlu U, Siva A (2018) Behçet’s syndrome and nervous system involvement. Curr Neurol Neurosci Rep 18(7):35. https://doi.org/10.1007/s11910-018-0843-5

    Article  PubMed  Google Scholar 

  15. Ghembaza MEA, Lounici A (2018) Superficial venous thrombosis in Behçet’s disease: a case report and a review of the literature. J Vasc Diagn Interv 6:15–18. https://doi.org/10.2147/JVD.S182929

    Article  Google Scholar 

  16. Giannessi C, Smorchkova O, Cozzi D et al (2022) Behçet’s disease: a radiological review of vascular and parenchymal pulmonary involvement. Diagnostics (Basel) 12(11):2868. https://doi.org/10.3390/diagnostics12112868

    Article  CAS  PubMed  Google Scholar 

  17. Hatemi I, Hatemi G, Çelik AF (2018) Gastrointestinal involvement in Behçet disease. Rheum Dis Clin North Am 44(1):45–64. https://doi.org/10.1016/j.rdc.2017.09.007

    Article  PubMed  Google Scholar 

  18. Erdem Sultanoğlu T, Eröz R, Ataoğlu S (2023) Evaluation of HLA-B51 frequency and its relationship with clinical findings in patients with Behçet’s disease: 4-year analysis in a single center. Egypt Rheumatol Rehabil 50(1):1–7. https://doi.org/10.1186/s43166-023-00181-1

    Article  Google Scholar 

  19. Alpsoy E, Leccese P, Emmi G, Ohno S (2021) Treatment of Behçet’s disease: an algorithmic multidisciplinary approach. Front Med 8:624795. https://doi.org/10.3389/fmed.2021.624795

    Article  Google Scholar 

  20. Rahman S, Daveluy S (2022) Pathergy test. StatPearls Publishing, Treasure Island

    Google Scholar 

  21. Bergamo S (2022) The diagnosis of Adamantiades-Behçet disease: clinical features and diagnostic/classification criteria. Front Med (Lausanne) 9:1098351. https://doi.org/10.3389/fmed.2022.1098351

    Article  PubMed  Google Scholar 

  22. Alibaz-Oner F, Direskeneli H (2021) Advances in the treatment of Behcet’s disease. Curr Rheumatol Rep 23(6):47. https://doi.org/10.1007/s11926-021-01011-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pérez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M (2021) Erythema nodosum: a practical approach and diagnostic algorithm. Am J Clin Dermatol 22(3):367–378. https://doi.org/10.1007/s40257-021-00592-w

    Article  PubMed  PubMed Central  Google Scholar 

  24. Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S (2018) Demographic and clinical features of Behcet’s disease in Azerbaijan. Int J Rheum Dis 21(5):1114–1119. https://doi.org/10.1111/1756-185X.12512

    Article  CAS  PubMed  Google Scholar 

  25. Sadeghi A, Rostami M, Amraei G, Davatchi F, Shahram F, KarimiMoghaddam A, KarimiMoghaddam Z, Zeraatchi A (2023) Clinical manifestations of Behçet’s disease: a retrospective cross-sectional study. Mediterr J Rheumatol 34(1):53–60. https://doi.org/10.31138/mjr.34.1.53

    Article  PubMed  PubMed Central  Google Scholar 

  26. İris M, Özçıkmak E, Aksoy A et al (2018) The assessment of contributing factors to oral ulcer presence in Behçet’s disease: dietary and non-dietary factors. Eur J Rheumatol 5(4):240–243. https://doi.org/10.5152/eurjrheum.2018.18094

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ciancio G, Colina M, La Corte R et al (2010) Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series. Rheumatology 49(3):501–504. https://doi.org/10.1093/rheumatology/kep401

    Article  CAS  PubMed  Google Scholar 

  28. Mattioli I, Bettiol A, Saruhan-Direskeneli G, Direskeneli H, Emmi G (2021) Pathogenesis of Behçet’s syndrome: genetic, environmental and immunological factors. Front Med 8:713052. https://doi.org/10.3389/fmed.2021.713052

    Article  Google Scholar 

  29. Alpsoy E, Bozca BC, Bilgic A (2021) Behçet disease: an update for dermatologists. Am J Clin Dermatol 22(4):477–502. https://doi.org/10.1007/s40257-021-00609-4

    Article  PubMed  Google Scholar 

  30. Bettiol A, Hatemi G, Vannozzi L, Barilaro A, Prisco D, Emmi G (2019) Treating the different phenotypes of Behçet’s syndrome. Front Immunol 10:2830. https://doi.org/10.3389/fimmu.2019.02830

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zou J, Luo JF, Shen Y et al (2021) Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther 23(1):45. https://doi.org/10.1186/s13075-021-02429-7

    Article  PubMed  PubMed Central  Google Scholar 

  32. Chen J, Yao X (2021) A contemporary review of Behcet’s syndrome. Clin Rev Allergy Immunol 61(3):363–376. https://doi.org/10.1007/s12016-021-08864-3

    Article  PubMed  Google Scholar 

  33. Karadag O, Bolek EC (2020) Management of Behcet’s syndrome. Rheumatology (Oxford) 59(3):108–117. https://doi.org/10.1093/rheumatology/keaa086

    Article  CAS  Google Scholar 

  34. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2020) One year in review 2020: Behçet’s syndrome. Clin Exp Rheumatol. 38(Suppl 127):3–10

    PubMed  Google Scholar 

  35. Khabbazi A, Ebrahimzadeh Attari V, Asghari Jafarabadi M, Malek Mahdavi A (2021) Quality of life in patients with Behçet disease and its relation with clinical symptoms and disease activity. Reumatol Clin 17(1):1–6. https://doi.org/10.1016/j.reuma.2019.03.002

    Article  PubMed  Google Scholar 

  36. Thomas T, Chandan JS, Subramanian A et al (2020) Epidemiology, morbidity and mortality in Behçet’s disease: a cohort study using The Health Improvement Network (THIN). Rheumatology (Oxford) 59(10):2785–2795. https://doi.org/10.1093/rheumatology/keaa010

    Article  PubMed  Google Scholar 

  37. Desbois AC, Terrada C, Cacoub P, Bodaghi B, Saadoun D (2018) Les manifestations oculaires de la maladie de Behçet [ocular manifestations in Behçet’s disease]. Rev Med Interne 39(9):738–745. https://doi.org/10.1016/j.revmed.2018.02.022

    Article  PubMed  Google Scholar 

  38. ÇakarÖzdal P (2020) Behçet’s uveitis: current diagnostic and therapeutic approach. Turk J Ophthalmol 50(3):169–182. https://doi.org/10.4274/tjo.galenos.2019.60308

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Assoc. Prof Doğan ÇAKAN, MD for proofreading, and Biostatistics Department of Istanbul University-Cerrahpaşa for checking the analysis.

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University-Cerrrahpasa, Istanbul, Turkey

    Zeliha Kübra Çakan

  2. Division of Rheumatology, Department of Internal Medicine, School of Medicine, Uludağ University, Bursa, Turkey

    Burcu Yağız & Yavuz Pehlivan

Authors
  1. Zeliha Kübra Çakan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Burcu Yağız
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yavuz Pehlivan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zeliha Kübra Çakan.

Ethics declarations

Conflict of interest

The authors have no conflict of interest, financial or otherwise. The authors are not related to any pharma company and this study was not financially supported by any institution. The authors have no conflicts of interest to declare relevant to this article’s content. This manuscript is original and it, or any part of it, has not been previously published; nor is it under consideration for publication elsewhere.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Çakan, Z.K., Yağız, B. & Pehlivan, Y. Clinical features of Behçet’s disease and prediction of the use of biologics in 488 cases: a single tertiary center study. Rheumatol Int 43, 2089–2097 (2023). https://doi.org/10.1007/s00296-023-05416-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-023-05416-0

Keywords

Search

Navigation